Alto Neuroscience ANRO Business Segments — Personnel expenses excluding stock-based compensation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's business segments — personnel expenses excluding stock-based compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's business segments — personnel expenses excluding stock-based compensation?
- Alto Neuroscience (ANRO) reported business segments — personnel expenses excluding stock-based compensation of $6.25M in Q1 2026.
- How has Alto Neuroscience's business segments — personnel expenses excluding stock-based compensation changed year-over-year?
- Alto Neuroscience's business segments — personnel expenses excluding stock-based compensation increased by 8.1% year-over-year, from $5.78M to $6.25M.
- What is the long-term trend for Alto Neuroscience's business segments — personnel expenses excluding stock-based compensation?
- Over 2 years (2023 to 2025), Alto Neuroscience's business segments — personnel expenses excluding stock-based compensation has grown at a 26.2% compound annual growth rate (CAGR), from $13.38M to $21.32M.
- What does business segments — personnel expenses excluding stock-based compensation mean?
- This metric represents the cash-based compensation costs, including salaries, bonuses, and benefits, for employees directly associated with the company's primary business operations. It excludes non-cash equity awards to provide a clearer view of the recurring operational cash burn required to maintain the workforce. Monitoring this helps investors assess the core human capital investment required to advance clinical-stage biopharmaceutical programs.